Loading stock data…
ResMed Inc. develops (RMD)
$195.27+3.38 (+1.76%)
Market ClosedLast close Jul 24
ResMed Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ResMed Inc. in the Healthcare sector is trading at $195.27 with a market capitalization of $28.3B. Wall Street consensus targets $248.60 (15 analysts), implying a +27.3% move over the next 12 months. The stock is currently near its 52-week low of $180.27, remaining 16.1% below its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +27.3% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 30) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.43B↑ | $1.42B↑ | $1.34B↓ | $1.35B↑ | $1.29B |
| Gross Profit | $890.98M↑ | $878.72M↑ | $820.82M | $820.07M↑ | $766.41M |
| Operating Income | $499.81M↑ | $497.60M↑ | $462.35M↑ | $456.57M↑ | $426.27M |
| Net Income | $398.73M↑ | $392.59M↑ | $348.54M↓ | $379.70M↑ | $365.04M |
Peer Comparison
JNJUNHPFE
Fundamentals
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sl...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.92%
ROE
Elite ROE. Management converts capital into profit efficiently.
23.41%
Volume
Today's trading volume
790,599
Recent News
3 Cash-Heavy Stocks to Research Further
A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital.
ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says
ResMed (RMD) is expected to post strong fiscal Q4 earnings growth, helped by an 8.6% rise in sales a
SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls
SpaceX initiated, Lululemon downgraded: Wall Street's top analyst calls
2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.